Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease?

Mounjaro (tirzepatide) - Eli Lilly

Zepbound (tirzepatide) - Eli Lilly

Switching from glucagon-like peptide-1 receptor agonists to tirzepatide in type 2 diabetes: does therapeutic sequencing matter for metabolic dysfunction-associated steatotic liver disease? (PubMed, J Diabetes Complications) - Sep 23, 2026 - No abstract available
Journal • Diabetes • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease • Type 2 Diabetes Mellitus

http://www.ncbi.nlm.nih.gov/pubmed/42772979

Christos S Mantzoros; Dimitrios Patoulias; Manfredi Rizzo

Sep 23, 2026